Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
Open Access
- 15 June 2023
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (4) , 100278
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 studyThe Lancet Haematology, 2019
- The changing face of immune tolerance induction in haemophilia A with the advent of emicizumabHaemophilia, 2019
- Emicizumab should be prescribed independent of immune tolerance inductionBlood Advances, 2018
- Risk factors for inhibitor development in severe hemophilia AThrombosis Research, 2018
- Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?Blood, 2017
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017
- Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance projectBlood, 2017
- Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia ANew England Journal of Medicine, 2016
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)Journal of Thrombosis and Haemostasis, 2011
- International workshop on immune tolerance induction: consensus recommendations1Haemophilia, 2007